Feasibility of a Bedtime Variability Protocol
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Emily Hohman, PhD
- Phone Number: 8148655245
- Email: eeh12@psu.edu
Study Locations
-
-
Pennsylvania
-
University Park, Pennsylvania, United States, 16802
- Pennsylvania State University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Child age 6-10 years
- Parent age 18 years or older
- Child has a regular bedtime (goes to bed within 30 minutes of the same time on 5 or more days per week)
Exclusion Criteria:
- Child has a medical condition impacting sleep (e.g., narcolepsy, sleep apnea)
- Child has a developmental disorder or delay (e.g., autism, Down syndrome)
- Child regularly takes supplements or medications (prescription or over the counter) for sleep, such as melatonin or antihistamines
- Not English speaking
- Not willing to follow bedtime protocol
- Residing in the same household as a current or previous participant (i.e., only 1 child per household may complete study)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Habitual bedtime
For one week, children will follow their habitual bedtime.
|
|
|
Experimental: Late bedtime
For one week, children will go to bed one hour later than their habitual bedtime
|
Participants will go to bed 1 hour later than their habitual bedtime
|
|
Experimental: Variable bedtime
For one week, children will go to bed at a prescribed time that will vary each day within +/- 1 hour of habitual bedtime.
|
Participants will go to bed at a prescribed time that varies each day within +/-1 hour of habitual bedtime
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to bedtime protocol
Time Frame: Daily during each of the 3, one-week intervention periods
|
Parents will report on the time their child went to bed
|
Daily during each of the 3, one-week intervention periods
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parent perception of feasibility of following the protocol (semi-structured interview)
Time Frame: At the end of 3 week study
|
Parents will provide qualitative answers to questions about their perceptions of following the protocol, including but not limited to whether the protocol was easy to follow, disruptive to their life, disruptive to their child's life.
|
At the end of 3 week study
|
|
Sleep duration
Time Frame: Daily during each of the 3, one-week intervention period
|
Child sleep duration during each intervention period, measured by actigraphy
|
Daily during each of the 3, one-week intervention period
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- STUDY00025204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.